ly2940094
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01263236)
Timeline
Indications
Mechanism of action
- Nociceptin receptorANTAGONIST
OPRL1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545406 ↗
Also known as
- ly2940094
- ly2940094
- ly2940094
- ly-2940094
- ly-2940094
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01798303 | Phase 2 | Jul 1, 2013 | Eli Lilly, Neumora Therapeutics, Inc. |
| NCT01724112 | Phase 2 | Nov 1, 2012 | Eli Lilly, Neumora Therapeutics, Inc. |
| NCT01404091 | Phase 1 | Jul 1, 2011 | Eli Lilly, Neumora Therapeutics, Inc. |
| NCT01263236 | Phase 1 | Dec 1, 2010 | Eli Lilly, Neumora Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 0 | 2 | 2010 |
| Neumora Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2010 |
2 organizations
Page 1 / 1